Meeting
2022 ASCO Annual Meeting
Association of 27-gene IO score with outcome in a phase Ib trial of pembrolizumab (pembro) plus chemotherapy (CT) in metastatic triple-negative breast cancer (mTNBC).
Authors
David B. Page
Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, OR
David B. Page , Krystle Louise Collins , Venkatesh Rajamanickam , Nicole Moxon , Staci L. Mellinger , Alison Katherine Conlin , Robert Seitz , Kim McGregor , Tyler J. Nielsen , Heather L. McArthur
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Triple-Negative
Clinical Trial Registration Number
NCT02734290
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1082)
DOI
10.1200/JCO.2022.40.16_suppl.1082
Abstract #
1082
Poster Bd #
460
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Pembrolizumab (pembro) with paclitaxel (taxol) or capecitabine (cape) as early treatment of metastatic triple-negative breast cancer (mTNBC).
First Author: David B. Page
Poster
2021 ASCO Annual Meeting
Saci-IO TNBC: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1– metastatic triple-negative breast cancer (mTNBC).
First Author: Ana Christina Garrido-Castro
Poster
2021 ASCO Annual Meeting
Multi-center randomized study of pembrolizumab/carboplatin versus carboplatin alone in patients with chest wall disease from breast cancer: TBCRC 044.
First Author: Neelima Vidula
Poster
2019 ASCO Annual Meeting
Anti-PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment for patients with metastatic NSCLC that were PD-L1 negative or less than 1 %.
First Author: Thierry Landre